Novo Nordisk informed Endpoints News it will discontinue its cell therapy research as part of a wider restructuring under CEO Maziar Mike Doustdar. The company—known for diabetes and obesity medicines—plans to reallocate resources toward core franchises, exiting a high‑cost, early‑stage modality. The move is the latest example of big pharma narrowing R&D scope and deprioritizing cell therapy discovery programs that require prolonged investment before near‑term commercial payoff.